Certifikované pracoviště
Státním úřadem pro kontrolu léčiv
Inovativní terapie
Klinické studie
našich přípravků
Bioinova
Česká biotechnologická společnost se sídlem v Praze zaměřující se na výzkum a vývoj moderní buněčné terapie.
Náš Tým



Napsali o nás
Projekty
Title of project: | Targeted and Improved Alzheimer's Disease Drug Development |
Registration number: | TO01000078 |
Researchers: | assoc. prof. PharmDr. Ondřej Soukup Ph.D. |
Contact person: | Mgr. Dora Truncová |
Programme Operator: | Technology Agency of the Czech Republic |
Funded by: | EEA (European Economic Area)/ Norwegioan Funds, The state budget of the Czech Republic |
Principal Investigator: | University Hospital Hradec Králové |
Consortioum members: | University of Oslo - Prof. Dr. copper. Dr. rer. nat. Jens Pahnke E.F.N. |
Institute of Experimental Medicine AS CR, v.v.i. - Mgr. Martin Horák Ph.D. | |
Bioinova, s.r.o. - MUDr. Peter Bauer Ph.D. | |
Timetable: | 1.1.2021 – 30.4.2024 |
Total budget: | max. fund: 35.212.148 Kč |
85 % z Norway grants: 29.930.325 Kč | |
15 % TA CR: 5.281.823 Kč |
The aim of the project is the development of compounds for the treatment of Alzheimer´s disease (AD). The project will include an approaches of personalized medicine during the development process in the way that novel compounds will be tested in a disease in a dish (DiD) model derived from AD patients.
The Targeted and Improved Alzheimer's Disease Drug Development benefits from a € (amount - use a rounded figure) grant from Norway Grants and Technology Agency of the Czech Republic within the KAPPA Programme.)